Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?

References

• Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol. Clin. North Am.34, 189–204 (2005).
   PubMed Web of Science ®Google Scholar
• Gilkin RJ. The spectrum of irritable bowel syndrome: a clinical review. Clin. Ther.27, 1696–1709 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol. Int.2, 92–95 (1989).
   Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut45(Suppl. II), II43–II47 (1999).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130, 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther.13(Suppl. 2), 31–38 (1999).
   PubMed Web of Science ®Google Scholar
• Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol. Motil.15, 79–86 (2003).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther.13, 1149–1159 (1999).
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther.14, 23–34 (2000).
   PubMed Web of Science ®Google Scholar
• Chang L, Ameen VZ, Dukes GE et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am. J. Gastroenterol.100, 115–123 (2005).
   PubMed Web of Science ®Google Scholar
• Krause R, Ameen V, Gordon SH et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am. J. Gastroenterol.102, 1709–1719 (2007).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet355, 1035–1040, (2000).
   PubMed Web of Science ®Google Scholar
• Lembo T, Wright RA, Lotronex Investigator Team et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol.96, 2662–2670 (2001).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med.161, 1733–1740 (2001).
   PubMed Web of Science ®Google Scholar
• van Wijngaarden I, Hamminga D, van Hes R et al. Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives. J. Med. Chem.36, 3693–3699 (1993).
   PubMed Web of Science ®Google Scholar
• Holger S, Chris E, Holger F et al. Metabolites of the 5-HT3 receptor antagonist cilansetron: characterization and biological activity. Neurogastroenterol. Motil.15, A208 (2003).
   Google Scholar
• Sann H, Reiche D, Thun-Battersby S. Comparison of cilansetron, alosetron and their metabolites: in vitro interaction with mechanisms other than 5-HT3. Gastroenterology128(Suppl. 2), A468 (2005).
   Google Scholar
• Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J. Pharmacol. Sci.104, 263–273 (2007).
   PubMedGoogle Scholar
• Bonnacker I, Koehn H, Kristen G, Reichel C. Cilansetron pharmaceutical preparation stabilized against racemization. Official Gazette of the United States Patent and Trademark Office Patents. 1228, November 2, no pagination (1999).
   Google Scholar
• Cilansetron. Investigational Drug Brochure, Sixth Edition. Solvay Pharma Deutschland, Hannover, Germany (1999).
   Google Scholar
• Chang J, Pardue R, Krinsky L, Fritsch H, Ducharme M, Brennan J. The single and multiple dose pharmacokinetics of 8 mg cilansetron in healthy elderly and young male and female subjects. AAPS Pharm. Sci.3, T3374 (2001).
   Google Scholar
• Pardue R, ZumBrunnen T, Fritsch H, DiSpirito M, Brennan J. A randomized, single-dose, two-period, crossover study to determine the effect of a liquid antacid on the pharmacokinetics of a 16 mg dose of cilansetron in healthy male and female volunteers. Pharmacotherapy22, 410 (2002).
   Google Scholar
• Pardue RL, Zipfel L, Fritsch H, Brennan J. The multiple dose pharmacokinetics of cilansetron in subjects with normal and impaired hepatic function. Clin. Pharmacol. Ther.73(Suppl. 2), P78 (2003).
   PubMedGoogle Scholar
• ZumBrunnen TL, Boon P, Chang J, de Vries M, Brennan JJ. The pharmacokinetics and pharmacodynamics of 17-d-norgestimate and ethinyl estradiol alone and in the presence of cilansetron 2 mg three-times daily, in healthy females. Clin. Pharmacol. Ther.77, P56 (2005).
   Google Scholar
• de Bruijn M, Boon P, ZumBrunnen TL, deVries M. Effect of fluvoxamine, paroxetine and ketoconazole on the multiple dose pharmacokinetics of cilansetron in healthy male and female volunteers. Clin. Pharmacol. Ther.77, P14 (2005).
   Google Scholar
• Morteau O, Julia V, Eeckhout C, Buéno L. Influence of 5-HT3 antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats. Fundam. Clin. Pharmacol.8, 553–562 (1994).
   PubMedGoogle Scholar
• Morteau O, Eeckhout C, Buéno L. Effect of the 5-HT3 antagonists (granisetron and KC9946) on viscerosensitive response to colorectal distension before and during experimental colitis in awake rats. Gastroenterology104(Suppl.), A1054 (1993).
   Google Scholar
• Botella A, Fioramonti J, Eeckhout C, Buéno L. Intracolonic glycerol induces abdominal contractions in rats: role of 5-HT3 receptors. Fundam. Clin. Pharmacol.12, 619–623 (1998).
   PubMedGoogle Scholar
• Hillsley K, Eeckhout C, Grundy D. Cilansetron acts at its site of absorption to antagonize the sensitivity of mesenteric afferent fibres to 5-hydroxytryptamine in the rat jejunum. Neurosci. Lett.278, 137–140 (2000).
   PubMed Web of Science ®Google Scholar
• Eeckhout C, Gregory P, David S. 5-HT3 antagonists prevent intraduodenal lipid induced slowing of gastric emptying in dogs. Gastroenterology106(Suppl), A492 (1994).
   Google Scholar
• Beglinger C, Hildebrand P, von Büren T, Krause G, Steinborn C, Drewe J. Effect of cilansetron, a specific 5-HT3 receptor antagonist, on gastrointestinal motor function in normal subjects. Naunyn Schmiedebergs Arch. Pharmacol.353(Suppl), R163 (1996).
   Google Scholar
• Frieling T, Becker K, Krause G, Steinborn C. Effects of oral cilansetron, a 5-HT3 antagonist, on oesophageal perception in healthy male volunteers. Digestion.59(Suppl. 3), B4191 (1998).
   Google Scholar
• Bruley des Varannes S, Zerbib F, Ropert A, Galmiche JP, Krause G, Steinborn C. Oral cilansetron increased threshold of gastric visceral perception in a placebo-controlled, double-blind study in healthy volunteers. Digestion.59(Suppl. 3), 226–227 (1998).
   Google Scholar
• Drewe J, Beglinger C, Meier R, Krause G, Steinborn C. Oral cilansetron produced increases in colonic transit time and gastric emptying in young and old healthy volunteers. Digestion.59(Suppl. 3), 665 (1998).
   PubMedGoogle Scholar
• Stacher G, Weber U, Stacher-Janotta G et al. Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. Br. J. Clin. Pharmacol.49, 1–8 (2000).
   PubMedGoogle Scholar
• Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study. Gastroenterology120(Suppl. 1), A217, Abstract 1139 (2001).
   Web of Science ®Google Scholar
• Caras S, Krause G, Biesheuvel E, Steinborn C. Cilansetron shows efficacy in non-constipated irritable bowel syndrome patients independent of the definition of the patient population by Rome I or Rome II. Gastroenterology120(Suppl. 1), A217, Abstract 1138 (2001).
   Web of Science ®Google Scholar
• Caras S, Carter F, Allgood A, Driessen S, Krause G, Steinborn C. Cilansetron shows an increase in adequate relief rate in non-constipated IBS subjects who respond as having no adequate relief at baseline. Gastroenterology122(Suppl), A550 (2002).
   Google Scholar
• Miner P, Stanton DB, Carter F, Caras S, Krause G, Steinborn C. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 3 month US study. Am. J. Gastroenterol.99(Suppl), S277 (2004).
   Google Scholar
• Mueller-Lissner S, Stanghellini V, Caras S et al. Cilansetron is efficacious in relieving abdominal pain/discomfort in men and women with irritable bowel syndrome with diarrhoea-predominance (IBS-D) in two multicenter studies. Gut53(Suppl. VI), 210 (2004).
   Google Scholar
• Clouse RE, Caras S, Cataldi F, Carter F, Krause G, Steinborn C. Cilansetron is efficacious for relief of urgency in patients with irritable bowel syndrome with diarrhoea-predominance (IBS-D). J. Pediatr. Gastroenterol. Nutrition.39(Suppl. 3), S777 (2004).
   Google Scholar
• Mayer EA, Miner PB, Caras S et al. Cilansetron is efficacious in the treatment of women with irritable bowel syndrome with diarrhoea-predominance (IBS-D): results from two multicenter trials. Gut53(Suppl. VI), 210 (2004).
   Google Scholar
• Coremans G, Clouse RE, Carter F, Krause G, Caras S, Steinborn C. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D). Gastroenterology126(Suppl. 2), A643 (2004).
   PubMedGoogle Scholar
• Monnikes H, Houghton LA, Carter F, Caras C, Krause G, Steinborn C. Cilansetron demonstrated relief from abdominal pain/discomfort in IBS with diarrhoea predominance. Gut54(Suppl. II), A115–116 (2005).
   Google Scholar
• Miner P, Novick JS. Long-term quality of life in patients with irritable bowel syndrome with diarrhea predominance (IBS-D) receiving cilansetron 2 mg three-times daily: results from a 52-week extension trial. Gastroenterology130(Suppl. 2), A598–599 (2006).
   Google Scholar
• Francisconi CF, Drossman DA, Mayer EA et al. Relief of symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) patients decreases after blinded withdrawal of cilansetron treatment. Gastroenterology128(Suppl. 2), A465 (2005).
   Google Scholar
• Bradette M, Moennikes H, Carter F, Krause G, Caras S, Steinborn C. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology126(Suppl. 2), A42 (2004).
   PubMed Web of Science ®Google Scholar
• Mearin F, Whorwell P, Carter F, Caras S, Krause G, Steinborn C. Cilansetron is efficacious in relieving bowel habit related symptoms in irritable bowel syndrome with diarrhoea-predominance. Gut54(Suppl. II), A18 (2005).
   PubMedGoogle Scholar
• Olden KW, Drossman DA, Carter F, Caras S, Krause G, Steinborn C. Cilansetron improves health-related quality of life in patients with irritable bowel syndrome with diarrhea-predominance (IBS-D). Am. J. Gastroenterol.99(Suppl), S277 (2004).
   Google Scholar
• Chey WD, Cash BD. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert. Opin. Investig. Drugs14, 185–193 (2005).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. LotronexR (alosetron hydrochloride) Tablets. Briefing Document for the Joint Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Committee. Vol. 1 (2002).
   Google Scholar
• Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am. J. Gastroenterol.99, 486–491 (2004).
   PubMed Web of Science ®Google Scholar
• Singh G, Mithal A, Triadafilopoulos G. Patients with irritable bowel syndrome have a high risk of developing ischemic colitis. Gastroenterology126(Suppl.), A41 (2004).
   Web of Science ®Google Scholar
• Suh DC, Kahler KH, Choi I-S, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment. Pharmacol. Ther.25, 681–692 (2007).
   PubMed Web of Science ®Google Scholar
• Holzer P, Painsipp E, Weber E, Pfannkuche H-J. 5-HT3 receptor antagonists, alosetron and cilansetron, impair mesenteric blood flow in rats. Gastroenterology124(Suppl. 1), A148–149 (2003).
   Google Scholar
• Patel SM, Stason WB, Legedza A et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil.17, 332–240 (2005).
   PubMed Web of Science ®Google Scholar